Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. (HALO) Stock Overview

Explore Halozyme Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

HALO●NASDAQ
HealthcareBiotechnology
$111.32
$2.58(2.27%)
U.S. Market is Open · 11:44

Halozyme Therapeutics, Inc. (HALO)

Meyka AI Score

Z

Key Financials

Market Cap13.4B
P/E Ratio32.19
EPS (TTM)$5.36
ROE1.81%
Fundamental Analysis

AI Price Forecasts

1 Month$98.39
3 Months$88.26
1 Year Target$85.32

HALO Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Halozyme Therapeutics, Inc. (NASDAQ: HALO) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, Halozyme Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of HALO on the NASDAQ shows an RSI of 60.36, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $85.32 for the NASDAQ listing.

Key metrics behind Halozyme Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of 32.19 and a market capitalization of 13.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of HALO on the NASDAQ.

Price Performance (NASDAQ: HALO)

1-Day Change
-0.89%
5-Day Change
-3.39%
1-Month Change
7.16%
3-Month Change
50.60%
6-Month Change
83.17%
Year-to-Date (YTD) Change
67.74%
1-Year Change
54.03%
3-Year Change
188.35%
5-Year Change
192.99%
All-Time (Max) Change
2556.24%

Contact Information

https://www.halozyme.com
858 794 8889
12390 El Camino Real, San Diego, CA, 92130

Company Facts

4,230 Employees
IPO DateMar 16, 2004
CountryUS
Actively Trading

Frequently Asked Questions